Ardelyx Inc
Company Profile
Business description
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Contact
400 Fifth Avenue
Suite 210
WalthamMA02451
USAT: +1 510 745-1700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
395
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,741.40 | 16.50 | -0.19% |
CAC 40 | 7,606.17 | 49.95 | -0.65% |
DAX 40 | 23,174.85 | 142.96 | -0.61% |
Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
FTSE 100 | 8,808.18 | 35.29 | -0.40% |
HKSE | 23,243.14 | 467.55 | -1.97% |
NASDAQ | 19,546.27 | 25.18 | 0.13% |
Nikkei 225 | 38,488.34 | 396.81 | -1.02% |
NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
S&P 500 | 5,980.87 | 1.85 | -0.03% |
S&P/ASX 200 | 8,523.70 | 7.50 | -0.09% |
SSE Composite Index | 3,362.11 | 26.70 | -0.79% |